In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae

Pathogens

Jared L. Crandon¹  David P. Nicolau¹ 

[1] Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; E-Mail:

关键词: Escherichia coli;    Klebsiella pneumonia;    ESBL;    carbapenemase;    β-lactamase inhibitor;   

DOI  :  10.3390/pathogens4030620

来源: mdpi

【 摘 要 】

We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to ≥3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs. Addition of AAI101 restored the activity of cefepime such that the MIC₅₀ was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/AAI101, supporting its continued development treatment for infections caused by these organisms.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.